

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	800 participants

Key Eligibility Criteria

Inclusion (9)

- Confirmed history of moderate-to-severe OSA
- Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening
- Have a BMI ≥ 27 kg/m² at screening
- Have a stable body weight ($\leq 5\%$ body weight change) for 90 days prior to screening
- Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

... and 4 more (see full listing online)

Exclusion (12)

- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed ≥ 1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Have had within 90 days prior to screening:

... and 7 more (see full listing online)

Locations (122 total)

Cullman Clinical Trials, Cullman, Alabama, United States
Ark Clinical Research, Long Beach, California, United States
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
... and 119 more locations